Boston Scientific director John E. Sununu to step down after 2026 annual meeting

Boston Scientific Corporation (NYSE:BSX), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $152 billion, announced Wednesday that John E. Sununu, a member of its board of directors since April 2009, has informed the company he will not stand for re-election at the 2026 annual meeting of stockholders. Sununu currently serves on the audit committee and is the chair of the nominating and governance committee.

According to a statement issued in an SEC filing, Sununu will continue to serve as a director and in his committee roles until the 2026 annual meeting. The company said Sununu’s decision is not the result of any disagreement with Boston Scientific.

The board of directors and its nominating and governance committee regularly review the size and composition of the board and will continue to evaluate whether to add directors following Sununu’s departure, according to the release.

This information is based on a company statement disclosed in a regulatory filing with the Securities and Exchange Commission.

In other recent news, Boston Scientific reported third-quarter net revenue of $5,065 million, reflecting a 15.3% year-over-year organic growth, surpassing analyst expectations. Canaccord Genuity maintained its Buy rating and set a price target of $132, noting the company’s strong performance. UBS also raised its price target to $140, highlighting Boston Scientific’s earnings per share growth and positive product cycle. Leerink Partners increased their price target to $130, acknowledging the company’s strong sales performance, with MedSurg and Cardiovascular sales exceeding consensus expectations. Goldman Sachs adjusted its price target to $124, citing Boston Scientific’s favorable growth outlook compared to its peers. Stifel reiterated its Buy rating with a $125 target, expressing confidence in the company’s double-digit revenue growth outlook for 2026-2028. These developments indicate that Boston Scientific is well-regarded by several analyst firms, with positive assessments of its recent performance and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.